Tempus Announces Seven Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2023

Tempus, a leader in artificial intelligence and precision medicine, today announced seven abstracts were accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 14-19, in Orlando, Florida. Tempus researchers will demonstrate how the company’s AI-enabled precision medicine platform collects and analyzes high-quality, multimodal datasets to advance cancer research.

“Tempus is excited to return to AACR and join the oncology research community in presenting our newest research, including how insights generated from our multimodal library led to an ongoing study exploring potential label expansion for a therapeutic for patients with PALB2 mutated tumors,” said Calvin Chao, MD, Senior Vice President of Medical Affairs at Tempus. 

This year, Tempus is sharing its latest collaborative scientific and clinical research findings via seven poster presentations. Highlights include: 

  • Poster Presentation (3148): Leveraging scale in precision oncology to measure pathway activation and detect genetic drivers in a large, real-world pan-cancer cohort
    • Session Date & Time: Monday, April 17, 2023; 1:30 p.m. – 5:00 p.m. ET
    • Location: Poster Section 33
    • Overview: Cancer tumorigenesis and progression are driven by genetic and epigenetic alterations, giving rise to transcriptional and pathway dysregulation. The Tempus team developed a machine learning platform that integrates DNA alterations and RNA expression data to measure the activation states of oncogenic signaling pathways and characterize novel genetic alterations that may cause pathway dysregulation, and tested it on Tempus’ multimodal database. Assessing both the level of pathway disruption and underlying genomic drivers may provide a more comprehensive understanding of tumor biology than assessing either factor alone.
  • Poster Presentation (CT055): PAVO: A phase-II, open label, single arm study of niraparib in patients with locally advanced/metastatic PALB2 mutated tumors
    • Session Date & Time: Monday, April 17, 2023; 9:00 a.m. – 12:30 p.m. ET
    • Location: Poster Section 46
    • Overview: PARP inhibitors have demonstrated efficacy in treating solid tumors with homologous recombination deficiency, the inability to repair DNA double-stranded breaks through the homologous recombination repair (HRR) pathway. While BRCA1/2 are instrumental to HRR, multiple genes, including PALB2, impact the HRR pathway. No clinically approved therapies specifically targeting PALB2 currently exist, however emerging evidence suggests that patients with germline or somatic PALB2 mutations may benefit from PARP inhibitor treatment. Tempus molecular data tracking (integrated NGS and EMR data) and the TIME Trial Program (rapid match of patients to Just in TIME sites for clinical trials), enabled patient identification and prescreening for this trial.


To learn more, visit https://www.tempus.com/events/aacr-2023/

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Related Content

View more
  • post image

    ADCs in focus: The next generation of precision medicine in oncology

    Watch this engaging discussion as thought leaders explore the evolving landscape of antibody-drug conjugates (ADCs) in cancer therapeutics, including resistance mutations in first-gen ADCs, combination strategies with immune checkpoint inhibitors (ICIs), and next-gen targets and technologies. Tempus is dedicated to enhancing ADC development by offering comprehensive genomic profiling, multimodal de-identified real-world data (RWD), and AI-enabled solutions, informing target discovery and clinical trial optimization for more personalized therapies.

    Watch replay
  • post image

    Advancing transcriptional cancer therapies with Tempus’ comprehensive life science solutions

    Kronos Bio, a trailblazer in the biopharmaceutical industry, is dedicated to the discovery and development of novel therapies that target transcriptional regulation in cancer. Kronos turned to Tempus’ comprehensive suite of solutions to propel its principal asset from discovery to clinical trials.


    Wednesday, July 31 @ 11am CT

    Integrating Omics in R&D: A new era of biomedical research

    Join us as we explore how multi-omics is reshaping the research landscape. Gain valuable insights from industry leaders as we: dive into the integration of diverse omics data, from NGS to proteomics, in research; discuss the transformative role of multi-omics in understanding complex disease mechanisms; and explore how multi-omics is personalizing clinical research for precision medicine.

    Read more
  • post image

    Accelerating ADC Development with Tempus AI

    Empowering precision and efficiency in ADC therapeutics with advanced data analytics

    Read more